Scarica l'app Stockscreener
1.38
2.13%
-0.03
Dopo l'orario di chiusura:
1.38
Precedente Chiudi:
$1.41
Aprire:
$1.39
Volume 24 ore:
1.88M
Relative Volume:
0.59
Capitalizzazione di mercato:
$369.67M
Reddito:
$236.20M
Utile/perdita netta:
$-5.35M
Rapporto P/E:
-77.09
EPS:
-0.0179
Flusso di cassa netto:
$67.70M
1 W Prestazione:
-0.72%
1M Prestazione:
+9.52%
6M Prestazione:
-49.08%
1 anno Prestazione:
-28.50%
Intervallo 1D:
$1.355
$1.3986
Intervallo di 1 settimana:
$1.30
$1.46
Portata 52W:
$1.14
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Nome
Akebia Therapeutics Inc
Settore
Telefono
617-871-2098
Indirizzo
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.38 | 369.67M | 236.20M | -5.35M | 67.70M | -0.0179 |
TAK
Takeda Pharmaceutical Co Adr
|
18.74 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.94 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.93 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.08 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
564.81 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-04-28 | Iniziato | Leerink Partners | Outperform |
| 2025-04-01 | Iniziato | Jefferies | Buy |
| 2023-11-29 | Ripresa | BTIG Research | Buy |
| 2023-08-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-31 | Downgrade | Needham | Buy → Hold |
| 2022-03-31 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Reiterato | Needham | Buy |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-11 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-02 | Iniziato | JP Morgan | Overweight |
| 2019-03-20 | Iniziato | Citigroup | Neutral |
| 2018-09-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Reiterato | Needham | Buy |
| 2018-06-06 | Reiterato | H.C. Wainwright | Buy |
| 2017-12-19 | Iniziato | Piper Jaffray | Overweight |
| 2017-12-07 | Iniziato | BTIG Research | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | Needham | Buy |
| 2016-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2016-12-20 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-11-15 | Iniziato | Aegis Capital | Buy |
| 2016-09-29 | Iniziato | Brean Capital | Buy |
| 2016-03-16 | Reiterato | Needham | Buy |
| 2016-01-21 | Iniziato | Credit Suisse | Neutral |
Mostra tutto
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
Aug Sectors: What is the next catalyst for Akebia Therapeutics Inc2026 Fed Impact & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D DaySlideshow (NASDAQ:AKBA) 2026-04-04 - Seeking Alpha
Akebia Therapeutics, Inc. (AKBA) stock price, news, quote and history - Yahoo Finance UK
Akebia (AKBA) director granted 214,400 options at $1.41, 3-year vest - Stock Titan
Akebia (NASDAQ: AKBA) director Philip J. Vickers files initial Form 3 - Stock Titan
Akebia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Akebia Therapeutics Issues Inducement Grants With Stock Options for New Employees - geneonline.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Akebia's Research and Development Day May Confirm or Undermine Its Kidney Treatment Strategy - Bitget
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia gives 13 new hires stock options for 679,900 shares - Stock Titan
AKBA: Vafseo and a robust pipeline drive growth, with major clinical milestones expected by 2027 - TradingView
AKBA: Innovative kidney disease pipeline advances with major clinical and commercial catalysts ahead - tradingview.com
Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline Targets - MarketBeat
Akebia Therapeutics Appoints Philip Vickers, Ph.D. to Board of Directors – Company Details and Nasdaq Listing (2026) - minichart.com.sg
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors - Sahm
Akebia Therapeutics appoints biopharmaceutical leader Philip Vickers to its board of directors - MarketScreener
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers To Its Board Of Directors - TradingView
Akebia Therapeutics adds Philip Vickers to board of directors By Investing.com - Investing.com India
Akebia Therapeutics (AKBA) appoints Philip Vickers to Board as Steven Gilman retires - Stock Titan
Akebia Therapeutics adds Philip Vickers to board of directors - Investing.com
AKBA.O PE Ratio & Valuation, Is AKBA.O Overvalued - intellectia.ai
AKBA Should I Buy - Intellectia AI
AKBA.O Technical Analysis & Stock Price Forecast - Intellectia AI
AKBA.O Stock News Today | Earnings, Events & Price Alerts - intellectia.ai
AKBA.O Forecast — Price Prediction for 2026. Should I Buy AKBA.O? - intellectia.ai
Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy - Insider Monkey
Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT - MSN
10 Best Penny Stocks That Could Triple Your Money - Insider Monkey
Nordea Investment Management Boosts Stake in Akebia Therapeutics - National Today
Nordea Investment Management AB Takes Position in Akebia Therapeutics, Inc. $AKBA - MarketBeat
Does Akebia Therapeutics Inc offer margin of safety2026 Top Decliners & Weekly Setup with High ROI Potential - baoquankhu1.vn
Fundamentals Check: What is the earnings history of Akebia Therapeutics IncEarnings Overview Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
US Market Recap: What is the next catalyst for Akebia Therapeutics IncPortfolio Growth Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Vanguard Disaggregates Holdings; Akebia (AKBA) Beneficial Ownership Reported as 0 - Stock Titan
Aug Retail: Is Akebia Therapeutics Inc stock showing strong momentum2026 Top Gainers & Capital Efficient Trading Techniques - baoquankhu1.vn
Street Watch: Can Akebia Therapeutics Inc benefit from deglobalization2026 Opening Moves & Daily Profit Focused Stock Screening - baoquankhu1.vn
Is the options market predicting a spike in Akebia Therapeutics stock? - MSN
Downgrade Watch: Should I invest in Akebia Therapeutics Inc before earnings2026 Performance Recap & Capital Efficiency Focused Ideas - baoquankhu1.vn
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Akebia Therapeutics, Inc. v. FibroGen, Inc. - Law.com
Trend Report: What is the earnings history of Akebia Therapeutics IncRecession Risk & Real-Time Buy Zone Alerts - baoquankhu1.vn
AKBA SEC FilingsAkebia Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 - The Manila Times
Akebia Announces Approval of Vafseo® (vadadustat) in Australia a - GuruFocus
Is the Options Market Signaling a Surge in Akebia Therapeutics Shares? - Bitget
Is the Options Market Predicting a Spike in Akebia Therapeutics Stock? - Yahoo Finance
Akebia Therapeutics (NASDAQ:AKBA) Stock Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Akebia Q2 2025 Earnings Preview - MSN
AKBA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus
Akebia Therapeutics Inc Azioni (AKBA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):